AVE

0.00%

0.2¢ avecho biotechnology limited

Ann: Avecho commences Phase III insomnia trial, page-16

First 16 Last

Share
Profile

Follow
playez

4,171 Posts.

68

04/04/24

12:21

Post #: 73186221
Share

Originally posted by Flectional: ↑

KK they will be lining up - insomnia and anxiety are an unmet need ....globally...

to ensure all the recruited for the trial meet the 'chronic sufferer ' classification for both placebo and treatment arms across a large and therefore statistically significant differentiation will delineate between success or failure to meet endpoint outcomes successfully.

Understanding the prevalence and criteria of chronic insomnia and the comorbidities that accompany it is key to successful recruitment and treatment outcome....patient cohort size is key hence the 500+ on this trial.
recruiting from that particular demographic clearly represented in the .prevalence' data is key -

'Various studies worldwide have shown the prevalence of insomnia in 10%–30% of the population, some even as high as 50%–60%. It is common in older adults, females, and people with medical and mental ill health.[4,5,6] The consequences of insomnia are significant, such as depression, impaired work performance, work- related/motor vehicle accidents, and overall poor quality of life. It is an easy-to-diagnose condition with many self-answerable questionnaires for aid, yet goes unrecognized in a significant number of patients coming to the outpatient department with other comorbid conditions. The objective of this study was to determine the prevalence of chronic insomnia, to look for any association with socioeconomic factors and medical comorbidities, and also to assess the patient's perception of having insomnia.'

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353813/#:~:text=Various%20studies%20worldwide%20have%20shown,medical%20and%20mental%20ill%20health.

mate we are not talking about the odd restless nights sleep here - we are talking unmet need with comorbidities that sit vacant in the Sched.3 treatment space - first mover will achieve market leverage in the space and attract BP for a red hot go...let alone achieve quality of life outcomes never before realised in that particular treatment titration for relief in the chronic cohort.

Anxiety is the moat

this is far from a 'Blackmores' off the shelf condiment

the numbers are correct on the skinny data available ....the real data as posted as an example by HT a few days back

Red or Black if your game for it

Expand

Flec' I'd suggest Blackmores ' condiments' would not see mixing vitamin E with cbd an all too high scientific fence to climb . However an excellent example of corporate inertia that would run straight over the top of the hapless ave . Of course the solubility compound will come with a different name.

AVE Price at posting: 0.5¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 2 more messages in this thread...

First 16 Last

Add AVE (ASX) to my watchlist

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $6.338M

Open	High	Low	Value	Volume
0.2¢	0.2¢	0.2¢	$20	10K

Buyers (Bids)

No.	Vol.	Price($)
35	45089096	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	46064683	27

View Market Depth

No.	Vol.	Price($)
35	45089096	0.002
18	33466742	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	46064683	27
0.004	34748864	17
0.005	15900219	9
0.006	17380067	10
0.007	5572471	5

Last trade - 14.12pm 27/09/2024 (20 minute delay)

AVE (ASX) Chart

Ann: Avecho commences Phase III insomnia trial, page-16

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Avecho commences Phase III insomnia trial, page-16

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News